Corvus Pharmaceuticals (CRVS) Change in Account Payables (2015 - 2026)

Corvus Pharmaceuticals' Change in Account Payables history runs 12 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Change in Account Payables rose 273.16% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $3.4 million, a 1225.91% increase from a year earlier, with the FY2025 full-year figure at -$91000.0, down 108.61% from the prior year.
• Change in Account Payables improved to $2.2 million in Q1 2026 per CRVS's latest filing, from $517000.0 in the prior quarter.
• Across five years, Change in Account Payables topped out at $2.2 million in Q1 2026 and bottomed at -$2.3 million in Q4 2022.
• The 5-year median for Change in Account Payables is $210000.0 (2022), against an average of $184235.3.
• Biggest YoY gain for Change in Account Payables was 561.87% in 2025; the steepest drop was 1616.67% in 2025.
• Year by year, Change in Account Payables stood at -$2.3 million in 2022, then soared by 105.38% to $121000.0 in 2023, then surged by 485.95% to $709000.0 in 2024, then declined by 27.08% to $517000.0 in 2025, then soared by 326.69% to $2.2 million in 2026.
• Per Business Quant, the three latest CRVS Change in Account Payables figures stand at $2.2 million (Q1 2026), $517000.0 (Q4 2025), and -$1.2 million (Q3 2025).